Navigation Links
VIDEO from Medialink and International HIFU: New Prostate Cancer Procedure Being Tested in US Clinical Trials
Date:1/29/2009

NEW YORK, Jan. 29 /PRNewswire/ -- According to the American Cancer Association, prostate cancer affects one in six men in the U.S. and is the second leading cause of cancer deaths in men. When caught and treated early, survival rates can be more than 90 percent, making swift treatment key.

(See video from International HIFU at: http://media.medialink.com/WebNR.aspx?story=36220)

Existing treatments however, can be limited and affect quality of life due to significant side effects, including loss of muscle mass, depression, decreased mental acuity and impotence. Now a High Intensity Focused Ultrasound (HIFU) procedure, available in 33 countries outside the US including Europe, is being tested in US Phase III clinical trials. HIFU is a minimally invasive procedure that uses the Sonablate(R) 500 ultrasound device to destroy cancerous tissue with focused sound waves.

By focusing sound waves in a targeted area, HIFU can rapidly increase the temperature in the focal zone, causing tissue destruction. This procedure is radiation-free and doesn't preclude any other treatment options.

For more information regarding the risks and benefits associated with HIFU, go to www.InternationalHIFU.com.

NOTE: Sonablate(R) 500 is not approved for use in the U.S. It remains investigational in the U.S. and is being studied as a prostate cancer treatment in clinical trials in the U.S. The FDA has made no decision as to the safety or efficacy of Sonablate(R) 500 for the treatment of prostate cancer. USHIFU is a worldwide leader in the development, distribution and use of minimally invasive high intensity focused ultrasound technologies. International HIFU is the entity through which USHIFU conducts its international business operations and makes the HIFU technologies available to US patients at centers outside the United States where such technologies are approved.

Registered journalists can access video, audio, text, graphics and photos for free and unrestricted use at http://www.mediaseed.tv.

01NY09-0045


'/>"/>
SOURCE Medialink; International HIFU
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Video: New Research Discovers Independent Brain Networks Control Human Walking
2. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
3. Video: The Arizona Heart Institute Announces the Largest Worldwide Experience with Endoluminal Grafting to Treat Thoracic Aortic Aneurysms and Related Pathologies
4. Video: Actress and New Mom Keri Russell Joins PKIDs to Launch Silence the Sounds of Pertussis Campaign
5. Video: Quest Diagnostics Health Trends(TM) Report Shows Significant Gap in Care for Patients With Chronic Kidney Disease
6. Video: New Results From One of the Worlds Largest Breast Cancer Trials Herald Hope for Thousands of Women
7. VIDEO: Femara(R) helps protect against return of breast cancer even when treatment starts several years after completing tamoxifen therapy
8. Vical Promotes Melanoma Awareness Month With Allovectin-7(R) Video Report
9. Video: The Journal, Human Genetics, Publishes Results Supporting Interleukin Genetics Heart Health Test
10. Discovering How Video Games Can Motivate Healthy Behaviors: More than $2 Million Awarded to 12 Research Teams Across U.S.
11. Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... AMSTERDAM , Feb. 27, 2017   ... AEX: PHIA), a global leader in health technology, ... and Drug Administration (FDA) to market its ElastQ ... EPIQ family of ultrasound systems. ElastQ Imaging enables ... stiffness, which is essential for the diagnosis of ...
(Date:2/27/2017)... 27, 2017  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ... company focused on tissue protection, repair and regeneration, ... Co., Ltd., received a positive response from the ... design for RGN-137 to treat epidermolysis bullosa ("EB"). ... incorporates Thymosin beta 4 ("Tß4") as the active ...
(Date:2/27/2017)... 2017  CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: ... M.D., Ph.D., as President and Chief Executive Officer (CEO) and ... Dr. Craig succeeds Richard Love , interim President and ... of Directors.  Dr. Craig has over 20 years of experience ... and Europe . "On behalf ...
Breaking Medicine Technology:
(Date:2/27/2017)... ... February 27, 2017 , ... Much attention has been paid to the ... dependent on opioid painkillers has fallen short. From 1999 until 2010, fatal overdoses from ... in fatal overdoses in male populations.(1) , The proportion of women using illicit drugs ...
(Date:2/27/2017)... Yorba Linda, Ca (PRWEB) , ... February 27, ... ... Coulter Life Sciences, provides an overview on laser diffraction analysis as a tool ... highlighting its capabilities, significance and potential to obtain improved results and novel scientific ...
(Date:2/27/2017)... ... February 27, 2017 , ... Sunshine Coast Health ... British Columbia, Canada, at https://www.sunshinecoasthealthcentre.ca/ , is proud to announce the addition ... Alsager, showcases the Centre's commitment to innovation in drug rehab and alcohol treatment ...
(Date:2/26/2017)... ... February 25, 2017 , ... The February 13, 2017, assassination ... and concern over nerve agents and the deadly use of chemical weapons. Many questions ... and how even small doses can be lethal. , Jay Jagannathan, M.D., of Michigan-based ...
(Date:2/26/2017)... ... February 26, 2017 , ... LatitudeC ... North America, today announced it would be offering some it’s exclusive product line ... on crafting quality and unique baby clothing/feeding products, will team up with AMAZON ...
Breaking Medicine News(10 mins):